Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Medical Devices industry M&A deals total $861.84m globally in February 2021

30 Mar 2021 (Last Updated March 30th, 2021 18:28)

Total medical devices industry M&A deals worth $861.84m were announced globally in February 2021, led by Veracyte’s $600m acquisition of Decipher Biosciences, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 96.4% over the previous month of $24.1bn and a drop of 88.4% when compared with the last 12-month average, which stood at $7.43bn.

Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $831.84m. At the country level, the US topped the list in terms of deal value at $831.84m.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in February 2021 was the US with 28 deals, followed by the Canada with four and Germany with two.

In 2021, as of February, medical devices M&A deals worth $24.96bn were announced globally, marking an increase of 1041.3% year on year.

medical devices industry M&A deals in February 2021: Top deals

The top five M&A deals accounted for 97.04% of the overall value during February 2021.

The combined value of the top five medical devices M&A deals stood at $836.34m, against the overall value of $861.84m recorded for the month.

The top five medical devices industry M&A deals of February 2021 tracked by GlobalData were:

1) Veracyte’s $600m acquisition of Decipher Biosciences

2) The $150m acquisition of Simplify Medical by NuVasive

3) Mind Medicine MindMed’s $32.66m acquisition of HealthMode

4) The $30m asset transaction with Earlysense by Hill-Rom Holdings

5) OncoCyte’s acquisition of Chronix Biomedical for $23.68m.